vs

Side-by-side financial comparison of PCB BANCORP (PCB) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

PCB BANCORP is the larger business by last-quarter revenue ($29.2M vs $27.6M, roughly 1.1× Zymeworks Inc.). On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs 11.3%). PCB BANCORP produced more free cash flow last quarter ($24.4M vs $-31.8M).

PCB Bank is an American community bank that focuses on the Korean-American community based in California and offers commercial banking services. It has branches in 8 states and is the third largest Korean American Bank after Bank of Hope and Hanmi Bank.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

PCB vs ZYME — Head-to-Head

Bigger by revenue
PCB
PCB
1.1× larger
PCB
$29.2M
$27.6M
ZYME
Growing faster (revenue YoY)
ZYME
ZYME
+61.3% gap
ZYME
72.6%
11.3%
PCB
More free cash flow
PCB
PCB
$56.2M more FCF
PCB
$24.4M
$-31.8M
ZYME

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
PCB
PCB
ZYME
ZYME
Revenue
$29.2M
$27.6M
Net Profit
$-19.6M
Gross Margin
Operating Margin
45.0%
-80.1%
Net Margin
-71.0%
Revenue YoY
11.3%
72.6%
Net Profit YoY
34.3%
EPS (diluted)
$0.65
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PCB
PCB
ZYME
ZYME
Q4 25
$29.2M
Q3 25
$30.4M
$27.6M
Q2 25
$29.3M
$48.7M
Q1 25
$26.9M
$27.1M
Q4 24
$26.2M
$31.0M
Q3 24
$25.3M
$16.0M
Q2 24
$24.2M
$19.2M
Q1 24
$23.9M
$10.0M
Net Profit
PCB
PCB
ZYME
ZYME
Q4 25
Q3 25
$11.4M
$-19.6M
Q2 25
$9.1M
$2.3M
Q1 25
$7.7M
$-22.6M
Q4 24
$-23.5M
Q3 24
$7.8M
$-29.9M
Q2 24
$6.3M
$-37.7M
Q1 24
$4.7M
$-31.7M
Operating Margin
PCB
PCB
ZYME
ZYME
Q4 25
45.0%
Q3 25
52.3%
-80.1%
Q2 25
43.3%
-1.4%
Q1 25
40.2%
-94.5%
Q4 24
39.3%
-71.6%
Q3 24
42.2%
-213.8%
Q2 24
36.3%
-222.9%
Q1 24
27.2%
-376.9%
Net Margin
PCB
PCB
ZYME
ZYME
Q4 25
Q3 25
37.5%
-71.0%
Q2 25
31.0%
4.8%
Q1 25
28.8%
-83.5%
Q4 24
-75.8%
Q3 24
30.8%
-186.6%
Q2 24
25.9%
-195.8%
Q1 24
19.6%
-315.6%
EPS (diluted)
PCB
PCB
ZYME
ZYME
Q4 25
$0.65
Q3 25
$0.78
$-0.26
Q2 25
$0.62
$0.03
Q1 25
$0.53
$-0.30
Q4 24
$0.46
$-0.32
Q3 24
$0.52
$-0.39
Q2 24
$0.43
$-0.49
Q1 24
$0.33
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PCB
PCB
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$207.1M
$64.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$390.0M
$320.1M
Total Assets
$3.3B
$397.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PCB
PCB
ZYME
ZYME
Q4 25
$207.1M
Q3 25
$369.5M
$64.8M
Q2 25
$263.6M
$98.3M
Q1 25
$214.3M
$76.2M
Q4 24
$198.8M
$66.1M
Q3 24
$193.1M
$122.4M
Q2 24
$177.6M
$71.0M
Q1 24
$239.8M
$114.8M
Stockholders' Equity
PCB
PCB
ZYME
ZYME
Q4 25
$390.0M
Q3 25
$384.5M
$320.1M
Q2 25
$376.5M
$334.5M
Q1 25
$370.9M
$325.0M
Q4 24
$363.8M
$338.8M
Q3 24
$362.3M
$367.0M
Q2 24
$353.5M
$406.2M
Q1 24
$350.0M
$438.0M
Total Assets
PCB
PCB
ZYME
ZYME
Q4 25
$3.3B
Q3 25
$3.4B
$397.3M
Q2 25
$3.3B
$408.4M
Q1 25
$3.2B
$425.5M
Q4 24
$3.1B
$463.1M
Q3 24
$2.9B
$487.2M
Q2 24
$2.9B
$515.6M
Q1 24
$2.9B
$553.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PCB
PCB
ZYME
ZYME
Operating Cash FlowLast quarter
$26.6M
$-31.4M
Free Cash FlowOCF − Capex
$24.4M
$-31.8M
FCF MarginFCF / Revenue
83.6%
-115.2%
Capex IntensityCapex / Revenue
7.5%
1.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$46.0M
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PCB
PCB
ZYME
ZYME
Q4 25
$26.6M
Q3 25
$16.4M
$-31.4M
Q2 25
$4.9M
$12.1M
Q1 25
$2.3M
$-3.4M
Q4 24
$39.0M
$-41.5M
Q3 24
$11.9M
$-5.9M
Q2 24
$14.6M
$-25.0M
Q1 24
$8.2M
$-37.7M
Free Cash Flow
PCB
PCB
ZYME
ZYME
Q4 25
$24.4M
Q3 25
$16.2M
$-31.8M
Q2 25
$3.8M
$11.6M
Q1 25
$1.6M
$-3.4M
Q4 24
$34.9M
$-41.8M
Q3 24
$11.9M
$-6.8M
Q2 24
$12.8M
$-25.6M
Q1 24
$6.0M
$-37.9M
FCF Margin
PCB
PCB
ZYME
ZYME
Q4 25
83.6%
Q3 25
53.2%
-115.2%
Q2 25
13.1%
23.7%
Q1 25
6.0%
-12.6%
Q4 24
133.2%
-134.8%
Q3 24
46.8%
-42.4%
Q2 24
53.1%
-133.0%
Q1 24
25.2%
-377.5%
Capex Intensity
PCB
PCB
ZYME
ZYME
Q4 25
7.5%
Q3 25
0.8%
1.5%
Q2 25
3.7%
1.1%
Q1 25
2.8%
0.1%
Q4 24
15.5%
1.0%
Q3 24
0.1%
5.6%
Q2 24
7.3%
3.1%
Q1 24
9.3%
1.8%
Cash Conversion
PCB
PCB
ZYME
ZYME
Q4 25
Q3 25
1.44×
Q2 25
0.54×
5.21×
Q1 25
0.30×
Q4 24
Q3 24
1.52×
Q2 24
2.33×
Q1 24
1.76×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons